Primary aldosteronism (PA) is the most common cause of secondary hypertension, accounting for up to 10% of hypertensive patients and an even higher proportion among those with resistant hypertension . Characterized by autonomous aldosterone secretion, PA leads to sodium retention, hypokalemia, and aldosterone-mediated cardiovascular and renal injury, resulting in substantially increased risks of s
Conditions
Interventions
Gold Standard:In individuals with primary aldosteronism (PA) considering surgery, we suggest adrenal lateralization with computed tomography (CT) scanning and adrenal venous sampling (AVS) prior to de
Index test:All participants will undergo CXCR4-PET/CT using 68Ga-Pentixafor or another approved CXCR4-targeted radiotracer according to the expert consensus .
Sponsors
Lanzhou University Second Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with PA in accordance with the "Expert Consensus on the Diagnosis and Treatment of Primary Aldosteronism" formulated by the Endocrinology Branch of the Chinese Medical Association in 2024; 2. According to the diagnostic criteria of the Chinese Hypertension Prevention and Control Guidelines (Revised Edition 2024), it is diagnosed as grade 2 or above hypertension; 3. Aged 18 to 70 years, signed the informed consent form agreeing to undergo adrenal CT, 68GA-pentixa for PET/CT and adrenal Vein sampling (AVS) for PA classification diagnosis; 4. Provide consultation on various treatment options for PA patients, including laparoscopic surgery (or robotic surgery), medication, and SAAE. The SAAE treatment plan that the patient agreed to accept.
Exclusion criteria
Exclusion criteria: 1. Patients with essential hypertension; 2. There is a history of severe cerebrovascular disease attacks such as transient cerebral ischemia, stroke, and cerebral hemorrhage within 6 months prior to admission; Or has experienced acute myocardial infarction or coronary stent implantation; 3. Patients with bilateral or unilateral renal artery stenosis, severe aortic stenosis, hyperkalemia or biliary obstruction within 12 months prior to admission to this trial; 4. Adrenal imaging suggests: Adenoma diameter > 2cm or more; For patients with renal function impairment within 4 weeks before admission: Serum creatinine >1.5 times the upper limit of the normal value; 6. Patients with severe liver diseases or liver dysfunction present with AST or ALT greater than three times the upper limit of the normal value; 7. Have a history of malignant tumors in the past five years, or are currently being evaluated for potential malignant tumors; 8. Patients with autoimmune diseases; 9. Patients who are allergic to or intolerant to contrast agents; 10. Positive pregnancy test results, lactating women, or women preparing for pregnancy 11. Patients with poor autonomous behavior ability (such as being unable to lie flat), severe claustrophobia, critically ill patients requiring life support, and those who are unable to cooperate in completing examinations and procedures. 12. The researchers determined that the subjects were not suitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactQiongying Wang
Lanzhou University Second Hospital
Outcome results
None listed